US 11,053,216 B2
Compounds and methods of use
Roopa Rai, San Francisco, CA (US); Sarvajit Chakravarty, San Francisco, CA (US); Brahmam Pujala, Noida (IN); Bharat Uttam Shinde, Noida (IN); Anjan Kumar Nayak, Noida (IN); Anil Kumar Agarwal, Noida (IN); Sreekanth A. Ramachandran, Noida (IN); and Son Minh Pham, San Francisco, CA (US)
Assigned to Medivation Technologies LLC, New York, NY (US)
Filed by Medivation Technologies LLC, New York, NY (US)
Filed on Oct. 22, 2019, as Appl. No. 16/659,775.
Application 16/659,775 is a continuation of application No. 15/933,532, filed on Mar. 23, 2018, granted, now 10,501,436.
Application 15/933,532 is a continuation of application No. 15/109,013, granted, now 10,030,004, issued on Jul. 24, 2018, previously published as PCT/US2014/072922, filed on Dec. 31, 2014.
Claims priority of application No. 6/DEL/2014 (IN), filed on Jan. 1, 2014.
Prior Publication US 2020/0071296 A1, Mar. 5, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/4709 (2006.01); C07D 213/72 (2006.01); C07D 213/73 (2006.01); C07D 213/82 (2006.01); A61K 45/06 (2006.01); A61K 31/506 (2006.01)
CPC C07D 401/12 (2013.01) [A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07D 213/72 (2013.01); C07D 213/73 (2013.01); C07D 213/82 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01)] 19 Claims
 
1. A method of providing a first or a second line therapy for treating (a) a breast cancer in an individual diagnosed with the breast cancer or (b) a prostate cancer in an individual diagnosed with the prostate cancer, comprising administering to the individual an effective amount of

OG Complex Work Unit Chemistry
4-(2-(5-chloro-2-fluorophenyl)-5-isopropylpyridin-4-ylamino)-N-(1,3-dihydroxypropan-2-yl)nicotinamide or a pharmaceutically acceptable salt thereof, thereby decreasing number of cancer cells, inhibiting cancer cell growth and/or proliferation, or increasing apoptosis of cancer cells.